The Burden of Small Fiber Neuropathy: Changes in Pain, Costs, and Quality of Life Before and After Diagnosis
Journal of the Peripheral Nervous System · 2026
DOI: 10.1111/jns.70153 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Peripheral Nervous System, 2026. Verfasst von Dennis Kool und 7 weiteren Autor:innen. Beteiligte Einrichtung: Mental Health and Neuroscience Research Institute, Maastricht University, Maastricht, the Netherlands. Hauptthemen laut MEDLINE: Quality of Life, Small Fiber Neuropathy, Cost of Illness, Health Care Costs. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Prinses Beatrix Spierfonds.
Abstract (Originalsprache)
Background and Aims Small fiber neuropathy ( SFN ) is a peripheral neuropathy causing neuropathic pain, reduced quality of life ( QoL ), and high societal costs. Previous studies assessed these societal costs before a definitive diagnosis was established, leaving it unclear whether diagnostic confirmation affects costs, pain intensity, or QoL . This study assessed changes in these outcomes before and after diagnosis.
Methods
Patients referred to the tertiary SFN expertise center in the Netherlands completed questionnaires before diagnosis (at placement on the waiting list, approximately 7 months before consultation) and at 3 and/or 6 months after confirmation. Healthcare utilization, patient and family costs, and productivity losses were assessed using the iMTA Medical Consumption and Productivity Cost Questionnaires. QoL was measured with the EQ‐5D‐5L and pain intensity with a numeric rating scale. Missing data were handled using multiple imputation, and changes over time were analyzed using within‐subject comparisons and generalized linear mixed models.
Results
Eighty‐four patients completed both pre‐ and postdiagnosis questionnaires. After follow‐up, total healthcare costs, patient and family costs, productivity losses, pain intensity, and QoL remained unchanged. However, diagnostic confirmation of SFN was associated with fewer medical specialist visits, lower related costs, and improved health perception.
Interpretation
These findings suggest that diagnostic clarification alone is insufficient to reduce the overall burden of SFN, highlighting the need for more effective symptom management and supportive care strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mental Health and Neuroscience Research Institute, Maastricht University, Maastricht, the Netherlands.
- Department of Neurology, Maastricht University Medical Center+, Maastricht, the Netherlands.
- Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Center (MUMC+), Maastricht, the Netherlands.
ORCID-Profile: Dennis Kool, Merel Kimman, Catharina G Faber, Janneke G J Hoeijmakers
Förderung
- Prinses Beatrix Spierfonds
Zitieren
APA
Kool, D., Geerts, M., Brandts, L., Kimman, M., Gorissen-Brouwers, C. M. L., Faber, C. G., Merkies, I. S. J., & Hoeijmakers, J. G. J. (2026). The Burden of Small Fiber Neuropathy: Changes in Pain, Costs, and Quality of Life Before and After Diagnosis. Journal of the Peripheral Nervous System. https://doi.org/10.1111/jns.70153
Vancouver
Kool D, Geerts M, Brandts L, Kimman M, Gorissen-Brouwers CML, Faber CG, et al. The Burden of Small Fiber Neuropathy: Changes in Pain, Costs, and Quality of Life Before and After Diagnosis. Journal of the Peripheral Nervous System. 2026. doi:10.1111/jns.70153
BibTeX
@article{Kool2026,
author = {Kool, Dennis and Geerts, Margot and Brandts, Lloyd and Kimman, Merel and Gorissen-Brouwers, Caroline M L and Faber, Catharina G and Merkies, Ingemar S J and Hoeijmakers, Janneke G J},
title = {The Burden of Small Fiber Neuropathy: Changes in Pain, Costs, and Quality of Life Before and After Diagnosis},
journal = {Journal of the Peripheral Nervous System},
year = {2026},
doi = {10.1111/jns.70153}
}
EUVIMED